

DAY	TIME	TYPE	3000	2010	2004	2011	2005	3022	POSTER HALL		
TUESDAY 2/16/10	8 am-1 pm	Workshop			1. PC Workshop for New Investigators and Trainees				Poster Set-up 7 am-9 pm		
	12 n-2 pm	Workshop			2. Frontiers in Lab Sci						
	2:30-4 pm	Opening Symposium	3. Guiding the Global Response								
	4-5 pm	Implementation Strategy Roundtable	4. The Future of PEPFAR								
	5:30-6:15 pm	Research Strategy Plenary	5. The HIV/AIDS Research Agenda: A View from NIAID								
	6:30-8 pm	Opening Plenaries	6. 15 <sup>th</sup> Bernard Fields Lecture 4 <sup>th</sup> N'Galy-Mann Lecture:								
	8-9 pm	Welcome Reception									
WEDNESDAY 2/17/10	8-8:30 am	Plenary	7. Putting the "C" into MTCT—Saving Kids							Posters Open 7 am-7 pm	
	8:30-9 am	Plenary	8. HIV-1 Assembly, Release, and Maturation								
	9:30 am-12 n	Oral Abstract Sessions			9. Developments in the Epi of SIV/HIV and AIDS-related Malignancies	10. Testing and Transmission	11. What's New in Immunopathogenesis	12. Advances in ART			
	1-2 pm	Themed Discussions	13. NeuroAIDS Treatment Issues and Controversies		14. What Monkey Models Can Teach Us about HIV Infection	15. Prediction of HIV Co-receptor Use	16. Hepatitis B and C: The Next Chapter in the Management of HIV in Resource-limited Countries	17. Got Milk? Vitamin D Deficiency Prevalence and Associations			
	2-4 pm	Poster Sessions									
	4-6 pm	Symposia					18. New Strategies for a Changing Epidemic	19. Targeting the HIV-1 Envelope Glycoprotein	20. Pathogenesis and Clinical Management of Complications		
THURSDAY 2/18/10	8:8:30 am	Plenary	21. The US Epidemic—Disparities in HIV Disease, Care, and Outcomes							Posters Open 7 am-7 pm	
	8:30-9 am	Plenary	22. Pathogenic vs Nonpathogenic Retrovirus Infections								
	9:30 am-12 n	Oral Abstract Sessions			23. HIV Vaccines: The Path Forward	24. Antiretroviral-based Prevention: Exposure and Efficacy 25. New Resistance Mechanisms and Detection Methods	26. New Insights into Retroviral Pathogenesis	27. TB Prevention and Treatment and Complications of HIV and ART 28. Progress and Problems in ART Rollout			
	1-2 pm	Themed Discussions	29. Impact of KIR/HLA on HIV Infection		30. Improving Estimates of HIV-1 Incidence	31. Viral Co-factors and Cellular Restrictions	32. HIV Drug Resistance in Breastfeeding Infants Exposed to ART	33. Progression of Atherosclerosis: Role of Inflammation and T Cell Activation			
	2-4 pm	Poster Sessions									
	4-6 pm	Symposia + Oral Abstract Session				34. Understanding the Variability of Drug Response	35. Challenges in HIV Prevention	36. HIV Replication: In and Out of the Cell	Oral Abstract Session 37. Long-term Complications: Hearts and Bones		
FRIDAY 2/19/10	8:8:30 am	Plenary	38. Mouse to Man? XMRV and Human Disease							Posters Open 7 am-7 pm	
	8:30-9 am	Plenary	39. HCV Entry: Unlocking the Door								
	9:30 am-12 n	Oral Abstract Sessions			40. New Insights into Transmission and Acute Infection	41. Virus-Host Interaction: HIV and XMRV	42. Treatment Outcomes in Women and Children	43. Hepatitis C: Transmission, Outcomes, and Treatment			
	1-2 pm	Themed Discussions	44. Antiretroviral Agent Penetration into Genital Secretions		45. NK Cells and ADCC: Linking Innate and Adaptive Immunity	46. Swine Flu Meets HIV	47. Impact of Treatment Intensification on HIV Reservoirs and Immune Activation	48. Renal Disease: Mechanisms and Outcomes			
	2-4 pm	Poster Sessions									
	4-6 pm	Symposia + Oral Abstract Session					Oral Abstract Session 49. Neuropathogenesis: Clinical Correlates and Impact of ART	50. New Insights into Mechanisms of T Cell Protection	51. The Future of HIV Therapeutic Research—The Treatment Agenda		
									Poster Removal 6-9 pm		